Zevra Therapeutics Q1 每股盈利 勝預期, 營收 低於預期
- 作者Investing.com
- •
Zevra Therapeutics, Inc. (Zevra), formerly KemPharm, Inc., is a rare disease company. The Company is engaged in creating therapies for diseases with limited or no treatment options. Its product include Arimoclomol, which is an orally-delivered, investigational product candidate for the treatment of Neimann-Pick type C (NPC). Its KP1077 is a lead clinical candidate being developed to treat idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), Zevra's prodrug of d-methylphenidate (d-MPH). The KP1077 orphan drug is used for the treatment of IH. The Company also offers AZSTARYS, which is a prodrug for the treatment of adult attention-deficit/hyperactivity disorder (ADHD) in patients age six years or older.